DK0813870T3 - Use of darifenacin to enhance cognitive functions - Google Patents

Use of darifenacin to enhance cognitive functions

Info

Publication number
DK0813870T3
DK0813870T3 DK97303879T DK97303879T DK0813870T3 DK 0813870 T3 DK0813870 T3 DK 0813870T3 DK 97303879 T DK97303879 T DK 97303879T DK 97303879 T DK97303879 T DK 97303879T DK 0813870 T3 DK0813870 T3 DK 0813870T3
Authority
DK
Denmark
Prior art keywords
darifenacin
cognitive functions
enhance cognitive
treatment
pharmaceutically acceptable
Prior art date
Application number
DK97303879T
Other languages
Danish (da)
Inventor
Michael John Allen
Brian Frank Johnson
Brian Robert Leaker
Robert Michael Wallis
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0813870T3 publication Critical patent/DK0813870T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)

Abstract

Darifenacin, and its pharmaceutically acceptable salts, are useful in the treatment of cognitive impairment. The invention also discloses the use of combinations of darifenacin, or a pharmaceutically acceptable salt thereof, with an acetylcholinesterase inhibitor, in the treatment of cognitive impairment.
DK97303879T 1996-06-18 1997-06-05 Use of darifenacin to enhance cognitive functions DK0813870T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612710.5A GB9612710D0 (en) 1996-06-18 1996-06-18 Method of treatment

Publications (1)

Publication Number Publication Date
DK0813870T3 true DK0813870T3 (en) 2003-08-18

Family

ID=10795468

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97303879T DK0813870T3 (en) 1996-06-18 1997-06-05 Use of darifenacin to enhance cognitive functions

Country Status (15)

Country Link
US (1) US5837724A (en)
EP (1) EP0813870B1 (en)
JP (1) JP3453493B2 (en)
KR (1) KR980000445A (en)
AT (1) ATE243514T1 (en)
AU (1) AU2495697A (en)
CA (1) CA2208111C (en)
DE (1) DE69722999T2 (en)
DK (1) DK0813870T3 (en)
ES (1) ES2197972T3 (en)
GB (1) GB9612710D0 (en)
HU (1) HUP9701060A3 (en)
IL (1) IL121036A0 (en)
PT (1) PT813870E (en)
ZA (1) ZA975311B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19707655A1 (en) * 1997-02-26 1998-08-27 Hoechst Ag Combination preparation for use in dementia
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
EP1615881A2 (en) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CA2718411C (en) 2008-03-27 2016-02-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HUE044653T2 (en) 2009-07-22 2019-11-28 PureTech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
CA3060030A1 (en) * 2017-06-01 2018-12-06 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
CA3180743A1 (en) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
EP0813870A1 (en) 1997-12-29
ZA975311B (en) 1998-12-17
HU9701060D0 (en) 1997-08-28
HUP9701060A2 (en) 1998-12-28
DE69722999D1 (en) 2003-07-31
DE69722999T2 (en) 2003-12-18
JPH1059848A (en) 1998-03-03
GB9612710D0 (en) 1996-08-21
HUP9701060A3 (en) 1999-03-29
KR980000445A (en) 1998-03-30
US5837724A (en) 1998-11-17
PT813870E (en) 2003-10-31
EP0813870B1 (en) 2003-06-25
ES2197972T3 (en) 2004-01-16
IL121036A0 (en) 1997-11-20
JP3453493B2 (en) 2003-10-06
AU2495697A (en) 1998-01-08
ATE243514T1 (en) 2003-07-15
CA2208111C (en) 2002-10-15
CA2208111A1 (en) 1997-12-18

Similar Documents

Publication Publication Date Title
PT936908E (en) UTERIC ANTICONVULSIVE DERIVATIVES IN THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS (ELA)
DE69721254T8 (en) Face mask with universal adjustment
DE69730043D1 (en) IMPLANTABLE ELETRODE LINE
LV12579B (en) The energy of the lawn and the change of energy
PT901487E (en) 4 (3H) -QUINAZOLINONES 2,3,6-TRISSUBSTITUIDES
DK0799819T3 (en) 1-Dimethylaminomethyl-2-phenylcycloalk-2-junctions having analgesic action
ID20531A (en) TREATMENT TOOL
DE69733470D1 (en) LASER TREATMENT
DK0813870T3 (en) Use of darifenacin to enhance cognitive functions
DE29609021U1 (en) safety goggles
TR199501714A1 (en) Chilling object with holes.
DE59702263D1 (en) Purification of p.p-bisphenolate solutions
DK1052991T3 (en) Topical use of loperamide for the treatment of microbial infections
DE29613426U1 (en) safety goggles
DE9319114U1 (en) Ear clip with replaceable cover, especially hearing aid in the form of an ear clip
IT233164Y1 (en) BRANDINA OR CUCCIA PIEGHEGOLE AND / OR REMOVABLE.
DK0661058T3 (en) Use of bradykinin antagonists in the treatment of viral diseases
FR2709944B1 (en) Surgical clip.
NL1000434C2 (en) Acetylene copolymers and membranes thereof.
ES1028150Y (en) PIECE OF BALLAST USED IN BELTS OF UNDERWATER ACTIVITIES.
ES1033996Y (en) GRAVES AND SIMILAR CRUSHER-SELECTOR MACHINE.
KR970050684U (en) Drowsiness Cap
KR900007413A (en) Prevention of AIDS, treatment and composition for the treatment
DE29606283U1 (en) Key, key head and key blank
FI962173A0 (en) With the aid of the sawmill